MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 275 filers reported holding MYRIAD GENETICS INC in Q4 2013. The put-call ratio across all filers is 4.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $41,572,749 | -32.9% | 2,591,588 | -3.1% | 0.01% | -30.0% |
Q2 2023 | $61,970,696 | -2.1% | 2,673,471 | -1.9% | 0.02% | -4.8% |
Q1 2023 | $63,285,535 | +165495.2% | 2,724,396 | +3.4% | 0.02% | +90.9% |
Q4 2022 | $38,217 | -99.9% | 2,633,864 | +8.3% | 0.01% | -38.9% |
Q3 2022 | $46,412,000 | +0.5% | 2,432,450 | -4.3% | 0.02% | +5.9% |
Q2 2022 | $46,174,000 | -28.5% | 2,541,207 | -0.8% | 0.02% | -15.0% |
Q1 2022 | $64,537,000 | -11.3% | 2,560,944 | -2.8% | 0.02% | -9.1% |
Q4 2021 | $72,748,000 | -16.1% | 2,635,803 | -1.9% | 0.02% | -21.4% |
Q3 2021 | $86,744,000 | +2.5% | 2,686,376 | -3.0% | 0.03% | +3.7% |
Q2 2021 | $84,666,000 | +2.1% | 2,768,704 | +1.4% | 0.03% | 0.0% |
Q1 2021 | $82,931,000 | +51.8% | 2,730,879 | -1.1% | 0.03% | +35.0% |
Q4 2020 | $54,619,000 | +51.2% | 2,762,037 | -0.3% | 0.02% | +33.3% |
Q3 2020 | $36,118,000 | +12.2% | 2,769,947 | -2.4% | 0.02% | +7.1% |
Q2 2020 | $32,183,000 | -24.7% | 2,838,177 | -4.9% | 0.01% | -36.4% |
Q1 2020 | $42,726,000 | -47.2% | 2,985,740 | +0.5% | 0.02% | -24.1% |
Q4 2019 | $80,894,000 | -4.3% | 2,970,889 | +0.7% | 0.03% | -12.1% |
Q3 2019 | $84,498,000 | +11.6% | 2,951,393 | +8.3% | 0.03% | +13.8% |
Q2 2019 | $75,727,000 | -13.0% | 2,726,076 | +4.0% | 0.03% | -17.1% |
Q1 2019 | $87,020,000 | +18.2% | 2,620,904 | +3.5% | 0.04% | +6.1% |
Q4 2018 | $73,645,000 | -39.4% | 2,533,403 | -4.1% | 0.03% | -28.3% |
Q3 2018 | $121,546,000 | +6.5% | 2,642,281 | -13.5% | 0.05% | 0.0% |
Q2 2018 | $114,175,000 | +9.9% | 3,055,263 | -13.1% | 0.05% | +7.0% |
Q1 2018 | $103,908,000 | -14.3% | 3,516,340 | -0.4% | 0.04% | -14.0% |
Q4 2017 | $121,303,000 | -6.3% | 3,531,884 | -1.3% | 0.05% | -12.3% |
Q3 2017 | $129,527,000 | +46.1% | 3,580,081 | +4.4% | 0.06% | +39.0% |
Q2 2017 | $88,636,000 | +74.7% | 3,430,216 | +29.8% | 0.04% | +70.8% |
Q1 2017 | $50,742,000 | +83.9% | 2,642,820 | +59.7% | 0.02% | +71.4% |
Q4 2016 | $27,587,000 | -7.6% | 1,654,854 | +14.1% | 0.01% | -12.5% |
Q3 2016 | $29,858,000 | -32.6% | 1,450,805 | +0.2% | 0.02% | -38.5% |
Q2 2016 | $44,324,000 | -16.9% | 1,448,505 | +1.7% | 0.03% | -18.8% |
Q1 2016 | $53,314,000 | -7.9% | 1,424,368 | +6.2% | 0.03% | -11.1% |
Q4 2015 | $57,881,000 | +27.0% | 1,341,041 | +10.3% | 0.04% | +20.0% |
Q3 2015 | $45,569,000 | +18.1% | 1,215,845 | +7.1% | 0.03% | +25.0% |
Q2 2015 | $38,584,000 | -4.1% | 1,135,183 | -0.1% | 0.02% | -4.0% |
Q1 2015 | $40,236,000 | +4.1% | 1,136,633 | +0.2% | 0.02% | 0.0% |
Q4 2014 | $38,648,000 | -10.2% | 1,134,659 | +1.7% | 0.02% | -19.4% |
Q3 2014 | $43,050,000 | -0.2% | 1,116,137 | +0.7% | 0.03% | +3.3% |
Q2 2014 | $43,157,000 | +15.9% | 1,108,845 | +1.8% | 0.03% | +7.1% |
Q1 2014 | $37,230,000 | +60.0% | 1,088,948 | -1.8% | 0.03% | +55.6% |
Q4 2013 | $23,272,000 | -11.6% | 1,109,258 | -1.0% | 0.02% | -21.7% |
Q3 2013 | $26,323,000 | +11.9% | 1,119,930 | +27.9% | 0.02% | +4.5% |
Q2 2013 | $23,528,000 | – | 875,624 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |